---
layout: post
title: "Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability"
date: 2026-02-05 18:59:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-14800
original_published: 2022-07-12 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 12, 2022 00:00 UTC
**Document Number:** 2022-14800

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Fresenius Kabi USA, LLC (Fresenius Kabi), for Fresenius Propoven 2% Emulsion. FDA revoked the Authorization on May 10, 2022, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/12/2022-14800/revocation-of-emergency-use-of-a-drug-during-the-covid-19-pandemic-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-14800

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
